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	 	 Overall 	 No	Diabetes 	 Diabetes
	 	 N	=	35,887 % 	 n	=	26,712 % 	 n	=	9,175 %
Age	in	years† 	 	 	 	 	 	 	 	 	
<20 	 159 0.4 	 143 0.5 	 10+	ǂ ǂ
20-29 	 3,082 8.6 	 2,814 10.5 	 268 2.9
30-39 	 8,165 22.8 	 6,903 25.8 	 1,262 13.8
40-49 	 12,764 35.6 	 9,519 35.6 	 3,245 35.4
50-59 	 9,007 25.1 	 5,815 21.8 	 3,192 34.8
60-69 	 2,605 7.3 	 1,459 5.5 	 1,146 12.5
70-79 	 100+	ǂ ǂ 	 50+	ǂ ǂ 	 45 0.5
≥80 	 ǂ ǂ 	 ǂ ǂ 	 ǂ ǂ
Sex† 	 	 	 	 	 	 	 	 	
Male 	 8,070 22.5 	 5,145 19.3 	 2,925 31.9
Female 	 27,817 77.5 	 21,567 80.7 	 6,250 68.1
IMD	Score† 	 	 	 	 	 	 	 	 	
Quin=le	1	(most	deprived) 	 11,132 31.0 	 8,445 31.6 	 2,687 29.3
Quin=le	2 	 8,930 24.9 	 6,661 24.9 	 2,269 24.7
Quin=le	3 	 6,684 18.6 	 4,873 18.2 	 1,811 19.7
Quin=le	4 	 5,245 14.6 	 3,819 14.3 	 1,426 15.5
Quin=le	5	(least	deprived) 	 3,815 10.6 	 2,846 10.7 	 969 10.6
Unknown/missing 	 81 0.2 	 68 0.3 	 12 0.1
Ethnicity† 	 	 	 	 	 	 	 	 	
White 	 25,834 72.0 	 19,032 71.3 	 6,802 74.1
Asian	or	Asian	Bri=sh 	 728 2.0 	 470 1.8 	 258 2.8
Black	or	Black	Bri=sh 	 1,458 4.1 	 1,111 4.2 	 347 3.8
Mixed 	 342 1.0 	 264 1.0 	 78 0.9
Other	Ethnic	Group 	 494 1.4 	 361 1.4 	 133 1.5
Unknown 	 7,031 19.6 	 5,474 20.5 	 1,557 17.0
Region† 	 	 	 	 	 	 	 	 	
North	East 	 3,579 10.0 	 2,662 10.0 	 917 10.0
North	West 	 2,316 6.5 	 1,915 7.2 	 401 4.4
Yorkshire	&	Humber 	 4,745 13.2 	 3,770 14.1 	 975 10.6
East	Midlands 	 2,679 7.5 	 2,050 7.7 	 629 6.9
West	Midlands 	 3,599 10.0 	 2,503 9.4 	 1,096 11.9
East	of	England 	 2,082 5.8 	 1,282 4.8 	 800 8.7
London 	 8,334 23.2 	 6,352 23.8 	 1,982 21.6
South	East 	 5,393 15.0 	 3,925 14.7 	 1,468 16.0
South	West 	 3,090 8.6 	 2,192 8.2 	 898 9.8
Unknown 	 70 0.2 	 61 0.2 	 9 0.1
Charlson	Comorbidity	Score† 	 	 	 	 	 	 	 	 	
0 	 28617 79.7 	 21775 81.5 	 6842 74.6
1	to	4 	 6451 18.0 	 4504 16.9 	 1947 21.2
5+ 	 819 2.3 	 433 1.6 	 386 4.2
Procedure	Type† 	 	 	 	 	 	 	 	 	
Gastric	Bypass 	 18,437 51.4 	 13,374 50.1 	 5,063 55.2
Gastric	Banding 	 8,259 23.0 	 6,431 24.1 	 1,828 19.9
Sleeve	Gastrectomy 	 5,809 16.2 	 4,429 16.6 	 1,380 15.0
Gastroplasty 	 3,382 9.4 	 2,478 9.3 	 904 9.9
Year	of	Surgery† 	 	 	 	 	 	 	 	 	
2006	-	2010 	 17,100 47.7 	 13,276 49.7 	 3,824 41.7






 Figure 1 - Kaplan Meier plots for all outcomes comparing people with and without diabetes 
Blue, solid line: without diabetes; Red, dotted line: with diabetes. Log-rank test p<0.001 for all outcomes. 
192x222mm (72 x 72 DPI)
 Figure 2 - Multivariable hazard ratio comparing mortality and other outcomes in people with and without diabetes after
bariatric surgery 
Estimates adjusted for age, sex, IMD score, ethnicity, region, modified Charlson Index and procedure type. 
1057x320mm (72 x 72 DPI)
 Figure 3 - Age-specific and age-standardised rate ratio for all-cause mortality following bariatric surgery in people with
and without diabetes compared to the general population 
Mortality rate ratios following bariatric surgery in patients with (full red squares) and without (empty blue squares) pre-
existing diabetes compared to the general population (England and Wales, 2015). 
890x932mm (72 x 72 DPI)
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Supplementary Table S1 - Classification for OPCS-4 Codes for bariatric surgery 
Exclusive 
G284 - Sleeve gastrectomy and duodenal switch 
G285 - Sleeve gastrectomy NEC 
G303 - Partitioning of stomach using band 
G716 - Duodenal switch 
G304 - Partitioning of stomach using staples 
G321 - Bypass of stomach by anastomosis of stomach to transposed jejunum 
G301 - Gastroplasty NEC 
G320 - Conversion from previous anastomosis of stomach to transposed jejunum 
G322 - Revision of anastomosis of stomach to transposed jejunum 
G323 - Conversion to anastomosis of stomach to transposed jejunum 
 
Non exclusive 
G312 - Bypass of stomach by anastomosis of stomach to duodenum 
G331 - Bypass of stomach by anastomosis of stomach to jejunum NEC 
G281 - Partial gastrectomy and anastomosis of stomach to duodenum 
G282 - Partial gastrectomy and anastomosis of stomach to transposed jejunum 
G283 - Partial gastrectomy and anastomosis of stomach to jejunum NEC 
G302 - Partitioning of stomach NEC 
G310 - Conversion from previous anastomosis of stomach to duodenum 
G313 - Revision of anastomosis of stomach to duodenum 
G314 - Conversion to anastomosis of stomach to duodenum 
G330 - Conversion from previous anastomosis of stomach to jejunum NEC 
G332 - Revision of anastomosis of stomach to jejunum NEC 
G333 - Conversion to anastomosis of stomach to jejunum NEC 
G335 - Closure of connection of stomach to jejunum NEC 
G336 - Attention to connection of stomach to jejunum 
G324 - Closure of connection of stomach to transposed jejunum 
G325 - Attention to connection of stomach to transposed jejunum 
 
Primary operation 
G284 - Sleeve gastrectomy and duodenal switch 
G285 - Sleeve gastrectomy NEC 
G303 - Partitioning of stomach using band 
G716 - Duodenal switch 
G304 - Partitioning of stomach using staples 
G321 - Bypass of stomach by anastomosis of stomach to transposed jejunum 
G301 - Gastroplasty NEC 
G312 - Bypass of stomach by anastomosis of stomach to duodenum 
G331 - Bypass of stomach by anastomosis of stomach to jejunum NEC 
G281 - Partial gastrectomy and anastomosis of stomach to duodenum 
G282 - Partial gastrectomy and anastomosis of stomach to transposed jejunum 
G283 - Partial gastrectomy and anastomosis of stomach to jejunum NEC 
G302 - Partitioning of stomach NEC 
 
Revision/Secondary operation 
G310 - Conversion from previous anastomosis of stomach to duodenum 
G313 - Revision of anastomosis of stomach to duodenum 
G314 - Conversion to anastomosis of stomach to duodenum 
G320 - Conversion from previous anastomosis of stomach to transposed jejunum 
G322 - Revision of anastomosis of stomach to transposed jejunum 
G323 - Conversion to anastomosis of stomach to transposed jejunum 
G330 - Conversion from previous anastomosis of stomach to jejunum NEC 
G332 - Revision of anastomosis of stomach to jejunum NEC 
G333 - Conversion to anastomosis of stomach to jejunum NEC 
G335 - Closure of connection of stomach to jejunum NEC 
G336 - Attention to connection of stomach to jejunum 
G324 - Closure of connection of stomach to transposed jejunum 
G325 - Attention to connection of stomach to transposed jejunum 
Supplementary Table S2 - ICD-10 codes for exposures and outcomes 
Conditions ICD-10 Codes 
Myocardial Infarction I21-I22, I25.2, 125.6 
Unstable Angina I20.0 
Stroke I60-I63 




Supplementary Table S3 - Number of patients identified through each code and 
category 
Codes Category No Diabetes Diabetes 
G281 - Partial gastrectomy and anastomosis of stomach to duodenum ByP 8 * 
G282 - Partial gastrectomy and anastomosis of stomach to transposed jejunum ByP 183 64 
G283 - Partial gastrectomy and anastomosis of stomach to jejunum NEC ByP 71 25 
G284 - Sleeve gastrectomy and duodenal switch ByP 49 11 
G285 - Sleeve gastrectomy NEC SG 4429 1,380 
G301 - Gastroplasty NEC GPl 322 119 
G302 - Partitioning of stomach NEC GPl 414 115 
G303 - Partitioning of stomach using band GB 6,431 1,828 
G304 - Partitioning of stomach using staples GPl 1,742 670 
G310 - Conversion from previous anastomosis of stomach to duodenum ByP 6 * 
G312 - Bypass of stomach by anastomosis of stomach to duodenum ByP 93 41 
G313 - Revision of anastomosis of stomach to duodenum ByP * * 
G314 - Conversion to anastomosis of stomach to duodenum ByP * 0 
G320 - Conversion from previous anastomosis of stomach to transposed jejunum ByP - - 
G321 - Bypass of stomach by anastomosis of stomach to transposed jejunum ByP 5,119 2,031 
G322 - Revision of anastomosis of stomach to transposed jejunum ByP 16 * 
G323 - Conversion to anastomosis of stomach to transposed jejunum ByP * * 
G324 - Closure of connection of stomach to transposed jejunum ByP * * 
G325 - Attention to connection of stomach to transposed jejunum ByP * 0 
G330 - Conversion from previous anastomosis of stomach to jejunum NEC ByP - - 
G331 - Bypass of stomach by anastomosis of stomach to jejunum NEC ByP 7,756 2,869 
G332 - Revision of anastomosis of stomach to jejunum NEC ByP 28 6 
G333 - Conversion to anastomosis of stomach to jejunum NEC ByP 13 * 
G335 - Closure of connection of stomach to jejunum NEC ByP * * 
G336 - Attention to connection of stomach to jejunum ByP * 0 
G716 - Duodenal switch ByP 16 * 
Total  26,712 9,175 
 
ByP=Bypass procedures, GPl=Gastroplasty, SG = Sleeve Gastrectomy, GB=Gastric Banding 
* number <5
Supplementary Table S4 - Multivariable cox proportional hazards regression models comparing mortality and other 
outcomes by diabetes status after bariatric surgery 






Stroke Heart failure Cancer 
Using only exclusive bariatric surgery codes 
Hazard Ratio (95% CI)* 1.33 (1.10-1.60) 1.66 (1.08-2.56)b 1.83 (1.24-2.46) 1.70 (1.18-2.46)c 1.63 (1.26-2.11)d 1.30 (1.11-1.51)e 
Using only primary bariatric surgery codes 
Hazard Ratio (95% CI)* 1.26 (1.08-1.47) 2.08 (1.42-3.04)b 1.80 (1.29-2.51) 1.58 (1.16-2.15)c 1.41 (1.13-1.75)d 1.22 (1.07-1.38)e 
 
*Using people without diabetes as a reference, adjusted for age, sex, IMD score, ethnicity, region, procedure type, b additionally excluding MI from Charlson index, c additionally excluding stroke 
from Charlson index, d additionally excluding heart failure from Charlson index e additionally excluding cancer from Charlson index 
Supplementary Figure S1 - Incidence rates (95% CI) for all outcomes following bariatric surgery in people with 
and without diabetes 
 
 




STROBE Statement—Checklist of items that should be included in reports of 
cohort studies 
 
Cardiovascular, cancer and mortality events after bariatric surgery in people with and 
without pre-existing diabetes: A nationwide study 
 
 Item No Recommendation Page 
 Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or 
the abstract 
1 
(b) Provide in the abstract an informative and balanced summary of what 
was done and what was found 
1 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being 
reported 
3 
Objectives 3 State specific objectives, including any prespecified hypotheses  3 
Methods  
Study design 4 Present key elements of study design early in the paper  4 
Setting 5 Describe the setting, locations, and relevant dates, including periods of 
recruitment, exposure, follow-up, and data collection 
 4 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection 
of participants. Describe methods of follow-up 
 4 
(b) For matched studies, give matching criteria and number of exposed 
and unexposed 
NA 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, 




8* For each variable of interest, give sources of data and details of methods 
of assessment (measurement). Describe comparability of assessment 
methods if there is more than one group 
 4-5 
Bias 9 Describe any efforts to address potential sources of bias  5-6 
Study size 10 Explain how the study size was arrived at  7 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why 
 5 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for 
confounding 
 5 
(b) Describe any methods used to examine subgroups and interactions  5 
(c) Explain how missing data were addressed  5 
(d) If applicable, explain how loss to follow-up was addressed NA 
(e) Describe any sensitivity analyses 5-6 
Results  
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, included 
in the study, completing follow-up, and analysed 
 7 
(b) Give reasons for non-participation at each stage  7 
(c) Consider use of a flow diagram - 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, 
social) and information on exposures and potential confounders 
 7 




(c) Summarise follow-up time (eg, average and total amount)  7 
Outcome data 15* Report numbers of outcome events or summary measures over time  7-8 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make clear 
which confounders were adjusted for and why they were included 
 7-8 
(b) Report category boundaries when continuous variables were 
categorized 
NA 
(c) If relevant, consider translating estimates of relative risk into absolute 
risk for a meaningful time period 
- 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, 
and sensitivity analyses 
 9 
Discussion  
Key results 18 Summarise key results with reference to study objectives  10 
Limitations 19 Discuss limitations of the study, taking into account sources of potential 
bias or imprecision. Discuss both direction and magnitude of any potential 
bias 
 10-11 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, 
limitations, multiplicity of analyses, results from similar studies, and other 
relevant evidence 
 11-12 
Generalisability 21 Discuss the generalisability (external validity) of the study results  12-13 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study 




*Give information separately for exposed and unexposed groups. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at http://www.strobe-statement.org. 
 
